Video
Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer
Author(s):
Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).
Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).
There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.
The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
